On Friday 24th March, Neuro-Bio was mentioned in the Health Investor UK.

The article talked about the current series C fundraise and the previous ones, quoting a message from CEO, Susan Greenfield : “It’s time we had a paradigm shift in AD. It’s time we started clearing the dogma that has prevailed and take a fresh approach. Something that started as academic idea that no one else believed ten years ago, is now suddenly getting traction. We have gone from a seemingly impossible dream to feasible vision, although there’s still a long way to go. Like a jigsaw puzzle, every time we obtain more data it just fits into the picture of the neurodegenerative process and validates it.”